Granted Patent B2

US 12,629,377 · App. 18/752,293 · Granted May 19, 2026

Inventors: Paul Sudhakar (Shawnee, KS); Scott Boyer (West Chicago, IL)

A61K31/53A61K9/0053A61K47/02A61K47/06A61K47/10A61K47/26A61K47/34A61K47/36A61K47/38

Abstract

Claims (92)

1 . A method for treating at least one of a neurological disorder and a mental disorder in a subject, the method comprising administering to a subject suffering from the disorder 0.1-25.0 mL of an oral liquid suspension comprising: lamotrigine, preservative, sweetener, solvent, anticaking agent, viscosifying agent, suspending agent, pH adjuster, and taste-masking agent;

wherein,

the lamotrigine comprises less than about 8 wt % lamotrigine hydrate;

the suspending agent comprises microcrystalline cellulose and colloidal silicon dioxide;

the oral liquid suspension is packaged in a glass or plastic bottle and the packaging further includes a syringe or cup, marked in mL, ounces, or both;

the glass or plastic bottle is configured for use to administer multiple doses of lamotrigine;

the oral liquid suspension has a viscosity at 25° C. of 100-200 mP;

the oral liquid suspension, while packaged in the container, is free from microbial contamination for at least 90 days under ambient conditions, wherein the microbial contamination includes less than 0.1 wt. % Escherichia coli ( E. coli ) and less than 0.1 wt. % Burkholderia cepacia complex (BCC); and

the oral liquid suspension is an immediate release dosage form that exhibits in-vitro dissolution rate more than 85% of drug release within 15 minutes, when said dosage form is placed in a dissolution vessel filled with 900 ml of 0.1N HCl, pH 1.2 maintained at 37+0.5° C. and stirred at a paddle speed of 50 rpm using a USP Type II (paddle) apparatus.

2 . The method of claim 1 , wherein the preservative comprises at least one of ethanol, benzoic acid, benzyl alcohol, bronopol, butylated hydroxyanisole (BHA), butylparaben, calcium acetate, calcium chloride, calcium lactate, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, citric acid monohydrate, ethylparaben, glycerin, hexetidine, imidurea, isopropyl alcohol, lactic acid, methylparaben, monothioglycerol, parabens, pentetic acid, phenoxyethanol, phenylethyl alcohol, potassium benzoate, potassium metabisulfite, potassium sorbate, propionic acid, propyl gallate, propylene glycol, propylparaben, propylparaben sodium, sodium acetate, sodium benzoate, sodium borate, sodium lactate, sodium metabisulfite, sodium propionate, sodium sulfite, sorbic acid, sulfobutyl ether β-cyclodextrin, edetic acid, thimerosal, and xanthan.

3 . The method of claim 1 , wherein the sweetener comprises at least one of acesulfame potassium, alitame, aspartame, dextrose, erythritol, fructose, glycerin, isomalt, lactitol, glucose, maltitol, maltose, mannitol, monk fruit extract, neohesperidin dihydrochalcone, neotame, saccharin, saccharin sodium, sodium cyclamate, sorbitol, stevia, sucralose, sucrose, tagatose, thaumatin, trehalose, and xylitol.

4 . The method of claim 1 , wherein the solvent comprises at least one of albumin, ethanol, almond oil, benzyl alcohol, benzyl benzoate, butylene glycol, castor oil, corn oil (maize), cottonseed oil, dimethyl ether, dimethylacetamide, ethyl lactate, ethyl oleate, glycerin, isopropyl alcohol, isopropyl myristate, isopropyl palmitate, light mineral oil, medium-chain triglycerides, methyl lactate, mineral oil, monoethanolamine, octyldodecanol, olive oil, peanut oil, polyethylene glycol, polyoxyl castor oil, propylene carbonate, propylene glycol, pyrrolidone, safflower oil, sesame oil, soybean oil, sunflower oil, triacetin, tricaprylin, triethanolamine, triethyl citrate, triolein, and water.

5 . The method of claim 1 , wherein the anticaking agent comprises at least one of tribasic calcium phosphate, calcium silicate, colloidal silicon dioxide, hydrophobic colloidal silica, magnesium oxide, magnesium silicate, magnesium trisilicate, and talc.

6 . The method of claim 1 , wherein the viscosifying agent comprises at least one of acacia, agar, alginic acid, bentonite, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, ceratonia, cetostearyl alcohol, chitosan, colloidal silicon dioxide, cyclomethicone, ethylcellulose, gelatin, glycerin, guar gum, hectorite, hydrogenated vegetable oil type I, hydrophobic colloidal silica, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, magnesium aluminum silicate, maltodextrin, methylcellulose, myristyl alcohol, polydextrose, polyethylene glycol, polyvinyl alcohol, potassium chloride, povidone, propylene glycol alginate, saponite, sodium alginate, sodium chloride, starch, stearyl alcohol, sucrose, sulfobutyl ether β-cyclodextrin, tragacanth, and xanthan gum.

7 . The method of claim 1 , wherein the pH adjuster comprises an acidifying agent comprising at least one of sodium phosphate dibasic, adipic acid, ammonium chloride, citric acid monohydrate, diluted hydrochloric acid, lactic acid, propionic acid, and tartaric acid.

8 . The method of claim 1 , wherein the taste-masking agent comprises a flavoring agent comprising at least one of cherry flavor, grape flavor, and peppermint flavor.

9 . The method of claim 1 , wherein the oral liquid suspension further comprises a coloring agent.

10 . The method of claim 1 , wherein the oral liquid suspension further comprises a coloring agent comprises FD&C red #40, FD&C yellow #6, or a combination thereof.

11 . The method of claim 1 , wherein the disorder comprises at least one of (a)-(c):

(a) epilepsy-adjunctive therapy in a subject aged 2 years or older:

partial-onset seizures

primary generalized tonic-clonic seizures

generalized seizures of Lennox-Gastaut syndrome;

(b) epilepsy-monotherapy in a subject aged 16 years and older: Conversion to monotherapy in a subject with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED; or

(c) bipolar disorder: maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in a subject treated for acute mood episodes with standard therapy.

12 . The method of claim 1 , wherein the oral liquid suspension is administered, such that

2±0.2 mg lamotrigine in 0.2 mL of the oral liquid suspension, or

5±0.5 mg lamotrigine in 0.5 mL of the oral liquid suspension, or

25±2.5 mg lamotrigine in 2.5 mL of the oral liquid suspension, or

100±10.0 mg lamotrigine in 10 mL of the oral liquid suspension, or

150±15.0 mg lamotrigine in 15 mL of the oral liquid suspension, or

200±20.0 mg lamotrigine in 20 mL of the oral liquid suspension is delivered to the subject.

13 . The method of claim 1 , wherein upon administration under fasted conditions of a healthy adult subject with epilepsy taking no other medications, the oral liquid suspension exhibits a single-dose administration pharmacokinetic (PK) profile including:

AUC, 0→24 of 88.1-198.8 micrograms per hour per ml;

C max steady state of 5.01-12.5 micrograms per ml;

T max of 0.00-8.0 h;

t 1/2 of 14.0-103.0 h when a single dose is administered; and

t 1/2 of 11.6-61.6 h when multiple doses are administered.

14 . The method of claim 1 , wherein upon administration under fasted conditions of a healthy adult subject with epilepsy taking no other medications, the oral liquid suspension exhibits a single-dose administration pharmacokinetic (PK) profile including:

AUC, 0→24 of 142 micrograms per hour per ml;

C max steady state of 7.93 micrograms per ml;

T max of 2.79 h;

t 1/2 of 32.8 h when a single dose is administered; and

t 1/2 of 25.4 h when multiple doses are administered.

15 . The method of claim 1 , wherein relative to oral tablets or chewable dispersible tablets containing an equivalent amount of lamotrigine, administration of the oral liquid suspension results in a lower incidence, severity, and/or duration of adverse reactions including at least one of dizziness, headache, diplopia, ataxia, nausea, blurred vision, somnolence, rhinitis, pharyngitis, rash, vomiting, infection, fever, accidental injury, diarrhea, abdominal pain, tremor, backpain, fatigue, and xerostomia.

16 . The method of claim 1 , wherein the lamotrigine in the oral liquid suspension has the following particle size distribution: D 90 of not more than 140 microns; D 50 of not more than 63 microns; and D 10 of not more than 26 microns.

17 . The method of claim 1 , wherein the lamotrigine in the oral liquid suspension has the following particle size distribution: D 90 of not more than 70 microns; D 50 of not more than 30 microns; and D 10 of not more than 10 microns.

18 . The method of claim 1 , wherein the oral liquid suspension is administered, such that

2±0.2 mg lamotrigine in 0.2 mL of the oral liquid suspension, or

5±0.5 mg lamotrigine in 0.5 mL of the oral liquid suspension, or

25±2.5 mg lamotrigine in 2.5 mL of the oral liquid suspension, or

100±10.0 mg lamotrigine in 10 mL of the oral liquid suspension, or

150±15.0 mg lamotrigine in 15 mL of the oral liquid suspension, or

200±20.0 mg lamotrigine in 20 mL of the oral liquid suspension

is delivered to the subject.

19 . The method of claim 1 , wherein upon administration under fasted conditions of a healthy adult subject with epilepsy taking no other medications, the oral liquid suspension exhibits a single-dose administration pharmacokinetic (PK) profile including:

AUC, 0→24 of 88.1-198.8 micrograms per hour per ml;

C max steady state of 5.01-12.5 micrograms per ml;

T max of 0.00-8.0 h;

t 1/2 of 14.0-103.0 h when a single dose is administered; and

t 1/2 of 11.6-61.6 h when multiple doses are administered.

20 . The method of claim 1 , wherein the oral liquid suspension has a viscosity at 25° C. of 117.5±20 mP.

21 . A method for treating at least one of a neurological disorder and a mental disorder in a subject, the method comprising administering to a subject suffering from the disorder 0.1-25.0 mL of an oral liquid suspension comprising:

lamotrigine having the following particle size distribution: D 90 of not more than 140 microns; D 50 of not more than 63 microns; and D 10 of not more than 26 microns, the lamotrigine comprising less than about 8 wt. % lamotrigine hydrate;

preservative comprising at least one of ethanol, benzoic acid, benzyl alcohol, bronopol, butylated hydroxyanisole (BHA), butylparaben, calcium acetate, calcium chloride, calcium lactate, cetrimide, cetylpyridinium chloride, chlorhexidine, chlorobutanol, chlorocresol, chloroxylenol, citric acid monohydrate, ethylparaben, glycerin, hexetidine, imidurea, isopropyl alcohol, lactic acid, methylparaben, monothioglycerol, parabens, pentetic acid, phenoxyethanol, phenylethyl alcohol, potassium benzoate, potassium metabisulfite, potassium sorbate, propionic acid, propyl gallate, propylene glycol, propylparaben, propylparaben sodium, sodium acetate, sodium benzoate, sodium borate, sodium lactate, sodium metabisulfite, sodium propionate, sodium sulfite, sorbic acid, sulfobutyl ether β-cyclodextrin, edetic acid, thimerosal, and xanthan;

sweetener comprising at least one of acesulfame potassium, alitame, aspartame, dextrose, erythritol, fructose, glycerin, isomalt, lactitol, glucose, maltitol, maltose, mannitol, monk fruit extract, neohesperidin dihydrochalcone, neotame, saccharin, saccharin sodium, sodium cyclamate, sorbitol, stevia, sucralose, sucrose, tagatose, thaumatin, trehalose, and xylitol;

solvent comprising at least one of albumin, ethanol, almond oil, benzyl alcohol, benzyl benzoate, butylene glycol, castor oil, corn oil (maize), cottonseed oil, dimethyl ether, dimethylacetamide, ethyl lactate, ethyl oleate, glycerin, isopropyl alcohol, isopropyl myristate, isopropyl palmitate, light mineral oil, medium-chain triglycerides, methyl lactate, mineral oil, monoethanolamine, octyldodecanol, olive oil, peanut oil, polyethylene glycol, polyoxyl castor oil, propylene carbonate, propylene glycol, pyrrolidone, safflower oil, sesame oil, soybean oil, sunflower oil, triacetin, tricaprylin, triethanolamine, triethyl citrate, triolein, and water;

anticaking agent comprising at least one of tribasic calcium phosphate, calcium silicate, colloidal silicon dioxide, hydrophobic colloidal silica, magnesium oxide, magnesium silicate, magnesium trisilicate, and talc;

viscosifying agent comprising at least one of acacia, agar, alginic acid, bentonite, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, ceratonia , cetostearyl alcohol, chitosan, colloidal silicon dioxide, cyclomethicone, ethylcellulose, gelatin, glycerin, guar gum, hectorite, hydrogenated vegetable oil type I, hydrophobic colloidal silica, hydroxyethyl cellulose, hydroxyethylmethyl cellulose, hydroxypropyl cellulose, hydroxypropyl starch, hypromellose, magnesium aluminum silicate, maltodextrin, methylcellulose, myristyl alcohol, polydextrose, polyethylene glycol, polyvinyl alcohol, potassium chloride, povidone, propylene glycol alginate, saponite, sodium alginate, sodium chloride, starch, stearyl alcohol, sucrose, sulfobutyl ether β-cyclodextrin, tragacanth, and xanthan gum;

suspending agent comprising microcrystalline cellulose and colloidal silicon dioxide;

pH adjuster, and taste-masking agent;

wherein,

the oral liquid suspension has a viscosity at 25° C. of 100-200 mP;

the oral liquid suspension is packaged in a glass or plastic bottle and the packaging further includes a syringe or cup, marked in mL, ounces, or both;

the oral liquid suspension is packaged in a glass or plastic bottle configured for use to administer multiple doses of lamotrigine;

the oral liquid suspension, while packaged in the container, is free from microbial contamination for at least 90 days under ambient conditions, wherein the microbial contamination includes less than 0.1 wt. % Escherichia coli ( E. coli ) and less than 0.1 wt. % Burkholderia cepacia complex (BCC);

the oral liquid suspension is an immediate release dosage form that exhibits in-vitro dissolution rate more than 85% of drug release within 15 minutes, when said dosage form is placed in a dissolution vessel filled with 900 ml of 0.1N HCl, pH 1.2 maintained at 37±0.5° C. and stirred at a paddle speed of 50 rpm using a USP Type II (paddle) apparatus.

22 . The method of claim 21 , wherein the disorder comprises at least one of (a)-(c):

(a) epilepsy-adjunctive therapy in a subject aged 2 years or older:

partial-onset seizures

primary generalized tonic-clonic seizures

generalized seizures of Lennox-Gastaut syndrome;

(b) epilepsy-monotherapy in a subject aged 16 years and older: Conversion to monotherapy in a subject with partial-onset seizures who are receiving treatment with carbamazepine, phenytoin, phenobarbital, primidone, or valproate as the single AED; or

(c) bipolar disorder: maintenance treatment of bipolar I disorder to delay the time to occurrence of mood episodes in a subject treated for acute mood episodes with standard therapy.

23 . The method of claim 21 , wherein upon administration under fasted conditions of a healthy adult subject with epilepsy taking no other medications, the oral liquid suspension exhibits a single-dose administration pharmacokinetic (PK) profile including:

AUC, 0→24 of 142 micrograms per hour per ml;

C max steady state of 7.93 micrograms per ml;

T max of 2.79 h;

t 1/2 of 32.8 h when a single dose is administered; and

t 1/2 of 25.4 h when multiple doses are administered.

24 . The method of claim 21 , wherein relative to oral tablets or chewable dispersible tablets containing an equivalent amount of lamotrigine, administration of the oral liquid suspension results in a lower incidence, severity, and/or duration of adverse reactions including at least one of dizziness, headache, diplopia, ataxia, nausea, blurred vision, somnolence, rhinitis, pharyngitis, rash, vomiting, infection, fever, accidental injury, diarrhea, abdominal pain, tremor, backpain, fatigue, and xerostomia.

25 . The method of claim 21 , wherein the lamotrigine in the oral liquid suspension has the following particle size distribution: D 90 of not more than 70 microns; D 50 of not more than 30 microns; and D 10 of not more than 10 microns.

Assignments (1)

Continuity (4)

References Cited (24)